Medication surveillance and clinical pharmacology of cancer drug treatment.
Onderwerp over onder andere polypharmacy bij personen met stemmingsstoornissen.
OSIBOOST 2 is a clinical trial designed to enhance the cost-effectiveness of Osimertinib for patients with Non-Small Cell Lung Cancer (NSCLC). Although Osimertinib significantly improves progression-free survival compared to older EGFRm-targeted therapies, its high cost remains a concern. To address this, the trial investigates the use of the CYP3A4 inhibitor Cobicistat, which reduces the metabolism of Osimertinib and increases its exposure (a process known as pharmacokinetic boosting). This approach allows patients to take a lower dose of Osimertinib while achieving the same therapeutic effect, potentially making the treatment more affordable without compromising its efficacy.
To demonstrate abnormalities in antibiotic pharmacokinetics and consequently antibiotic exposure in critically ill patients